Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1]. |
In vitro | Anticancer agent 74 exhibits low cytotoxicity in HepG2 (IC 50 : 72.27 μM), A549 (IC 50 : 70.79 μM), HuCCA-1 (IC 50 : 70.42 μM), and MOLT-3 (IC 50 : 20.71 μM) cell lines, alongside low selectivity with IC 50 values of 0.88 μM for HepG2, 5.08 μM for A549, 5.11 μM for HuCCA-1, and 17.39 μM for MOLT-3, respectively [1]. Despite its good cytotoxic effects, the compound demonstrates low selectivity across these primary cancer cell types, as assessed in cytotoxicity assays involving the A549, HuCCA-1, HepG2, and MOLT-3 cell lines. |
分子量 | 351.44 |
分子式 | C25H21NO |
CAS No. | 2242503-82-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Anticancer agent 74 2242503-82-6 Inhibitor inhibitor inhibit